Loading…
BeyondSpring Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -94.4% over 5Y.
today you would have $49.31▼ -95.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 9 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.63 | $1.63 | $0.90 | $1.88 | $4.53 | $12.20 | $15.50 | $18.75 | $29.08 | |
| P/S | 130.5x | — | — | — | 54.3x | 130.5x | 2653.0x | — | — | — |
| P/B | 10.4x | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PLRZPolyrizon Ltd. | $13.15 | — | 1.0x | — | -25.38% | $27.39M |
| CVMCel Sci Corp | $1.56 | — | 2.5x | — | -252.53% | $27.44M |
| ARAYAccuray Inc | $0.23 | — | 0.6x | — | -80.08% | $26.93M |
| FEMYFemasys Inc | $3.20 | — |
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Company description provided by Yahoo Finance.
| — |
| — |
| 6.6x |
| 5.4x |
| 14.3x |
| — |
| 24.2x |
| EPS | -$0.02 | -$0.28 | -$0.54 | -$0.85 | -$1.64 | -$2.03 | -$1.55 | -$2.42 | -$4.40 |
| Profit margin | -4750.48% | — | — | — | -2463.29% | -4750.48% | -33873.89% | — | — | — |
| ROE | -183.15% | — | — | — | — | -240.51% | -69.02% | -125.79% | — | -338.91% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 2.4x |
| — |
| -424.97% |
| $26.8M |
| OPTHOptimi Health Corp. | $4.93 | — | 2.2x | — | -54.36% | $28.2M |
| MODDModular Medical, Inc. | $3.46 | — | 1.2x | — | -247.94% | $28.2M |